Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 12;616(7957):525–533. doi: 10.1038/s41586-023-05783-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, Signature profiles of SBS4 and SBS92 as reported using COSMIC (v.3.2). b, The correlation between smoking-mediated mutations (SBS4 and SBS92) and pack-years in 386 LUAD and LUSC tumours from patients with a smoking history. Pearson’s correlation tests were used. c, Cumulative percentage of all LUAD tumours with SBS4 detection or lack of SBS4 detection with increasing maximum years smoked. A total of 223 tumours were analysed. d, Comparison of pack-years between patients with LUAD with different SBS4 detection statuses in their tumour. A total of 215 patients were included. Each data point represents a patient with LUAD and an ever-smoker. e, The percentage of LUAD tumours harbouring EGFR mutations, RET–ROS1–ALK oncogenic fusions and MET exon-skipping events in patients who never smoked and in patients who have smoked split by SBS4 detection status. A total of 248 tumours were included. f, Frequency of tumours in the TRACERx 421 cohort located in each lung lobe and the median number of truncal SBS4-associated mutations for tumours located in each lung lobe. A total of 358 LUAD and LUSC tumours from ever-smokers were included. LLL, left lower lobe; LUL, left upper lobe; RML, right middle lobe; RLL, right lower lobe; RUL, right upper lobe. The schematic in f was created using BioRender (https://biorender.com).